MILAN, Dec. 20 (Class Editori) — GVS, leading company in the supply of advanced filtration solutions for highly critical applications, has entered — through its wholly-owned subsidiary GVS Technology (Suzhou) — into a binding agreement with Ningbo Fuji Medical Technology, a subsidiary of Shanghai Fosun Pharmaceutical Group, in order to acquire the entire share capital of Shanghai Transfusion Technology (STT), a Shanghai-based company active in the production and sale of blood management-related tolls.
According to the official statement, the acquisition of the company represents a unique strategic opportunity for GVS to fully enter the Chinese healthcare market, with the possibility of achieving commercial, industrial and branding synergies.
"Thanks to the acquisition of STT, historic leader in China's blood management sector, we are now in a privileged position to expand our Group's presence in the Chinese market. This acquisition, together with the recent opening of three distribution centres in Malaysia, Thailand and Vietnam, will allow us to consolidate our position in the Chinese and Asian healthcare segments by promoting our entire product line," Massimo Scagliarini, CEO of GVS, stated.
For over 30 years, STT has been operating in the blood management sector, and it mainly supplies blood centres and hospitals in the Chinese market. STT and its subsidiary Suzhou Laishi Transfusion Equipment are specialized in R&D, and production and sale of blood management-related tools (e.g., plasma sterilization, leuco-depletion filters and blood transfusion bags, medicines and accessories).
STT's business focuses solely on the domestic market and its activities are carried out in the production centre in Shanghai, based in one of the main areas of the city, and valued by GVS through an estimate by external experts at approximately 120 million yuan, namely around16.6 million euros. (All rights reserved)
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.